our Premium Content: News alerts, weekly reports and conference planners

DRUG:

NKG2D CAR-NK cell therapy

News alerts, weekly reports and conference planners

Company:

Hangzhou Cheetah Cell Therap

Drug class:

NK cell stimulant, NKG2DL-targeted CAR-T immunotherapy

Related drugs:

cytotoxic lymphocyte-based cancer vaccine (0)

GCC4001 (0)

CAR-ITNK cells (0)

CAR-NK-CD19 cells (0)

CAR.70/IL15-transduced CB-NK cells (0)

CAR19-CYNK (0)

CB CAR-NK019 (0)

CBT101 (0)

CD123 targeted CAR-NK (0)

CD33/CLL1 dual CAR-NK cell (0)

CDH17 CAR-NK cell therapy (0)

CHM 2301 (0)

CIML NK (0)

CLDN6-CAR-NK cell therapy (0)

DC vaccine for prostate cancer (0)

primed NK cell therapy (0)

NK/γδ T cell-enriched cell therapy (0)

NK92-CD16-158V (0)

NKG2D-CAR-NK92 cells (0)

Super NK cell therapy (0)

TROP2-CAR-NK (0)

UD TGFbetai NK cells (0)

›

NKG2D CAR-NK & r/rAML (NCT05734898)

Phase N/A

Zhejiang University

Recruiting

Phase N/A

Zhejiang University

Recruiting

Last update posted :

03/03/2023

Initiation :

03/01/2023

Primary completion :

04/01/2024

Completion :

09/01/2024

NKG2D

NKG2D CAR-NK cell therapy

NKG2D CAR-NK cell therapy

Trials

Trials